Similar articles for PMID: 22442104

Year	Number of Results
2001	1
2004	2
2005	2
2006	13
2007	8
2008	6
2009	6
2010	4
2011	9
2012	3
2013	1
2014	6
2015	3
2016	5
2017	1
2018	1
2019	1
2024	0

1

A broader importance of NOPR to the future of nuclear imaging.

Hillman BJ. Hillman BJ. J Nucl Med. 2012 May;53(5):677-8. doi: 10.2967/jnumed.112.104968. Epub 2012 Mar 21. J Nucl Med. 2012. PMID: 22442104 Free article. No abstract available.

2

Impact on Patient Management of [18F]-Fluorodeoxyglucose-Positron Emission Tomography (PET) Used for Cancer Diagnosis: Analysis of Data From the National Oncologic PET Registry.

Subramaniam RM, Shields AF, Sachedina A, Hanna L, Duan F, Siegel BA, Hillner BE. Subramaniam RM, et al. Oncologist. 2016 Sep;21(9):1079-84. doi: 10.1634/theoncologist.2015-0364. Epub 2016 Jul 8. Oncologist. 2016. PMID: 27401896 Free PMC article.

3

The National Oncologic PET Registry: expanded medicare coverage for PET under coverage with evidence development.

Lindsay MJ, Siegel BA, Tunis SR, Hillner BE, Shields AF, Carey BP, Coleman RE. Lindsay MJ, et al. AJR Am J Roentgenol. 2007 Apr;188(4):1109-13. doi: 10.2214/AJR.06.1175. AJR Am J Roentgenol. 2007. PMID: 17377055

4

2014 Cassen Lecture: What have we learned from the National Oncologic PET Registry?

Siegel BA. Siegel BA. J Nucl Med. 2014 Dec;55(12):9N-15N. J Nucl Med. 2014. PMID: 25453061 Free article. No abstract available.

5

Positron-emission tomography in cancer therapy.

Meyer MA. Meyer MA. N Engl J Med. 2006 May 4;354(18):1958-60; author reply 1958-60. doi: 10.1056/NEJMc060556. N Engl J Med. 2006. PMID: 16672712 No abstract available.

6

[Therapeutic response evaluation by nuclear functional imaging].

Moretti JL, Hindie E, Vercellino L. Moretti JL, et al. Bull Cancer. 2007;94(7 Suppl):F241-4. Bull Cancer. 2007. PMID: 17965003 French.

7

Positron-emission tomography and assessment of cancer therapy.

Juweid ME, Cheson BD. Juweid ME, et al. N Engl J Med. 2006 Feb 2;354(5):496-507. doi: 10.1056/NEJMra050276. N Engl J Med. 2006. PMID: 16452561 Review. No abstract available.

8

Quantitative PET factors predictive of the response to therapy in solid tumors: which is the best?

Maffione AM, Grassetto G, Chondrogiannis S, Colletti PM, Rubello D. Maffione AM, et al. Clin Nucl Med. 2014 Feb;39(2):160-3. doi: 10.1097/RLU.0000000000000319. Clin Nucl Med. 2014. PMID: 24321831 Review. No abstract available.

9

The National Oncologic PET Registry (NOPR): design and analysis plan.

Hillner BE, Liu D, Coleman RE, Shields AF, Gareen IF, Hanna L, Stine SH, Siegel BA. Hillner BE, et al. J Nucl Med. 2007 Nov;48(11):1901-8. doi: 10.2967/jnumed.107.043687. Epub 2007 Oct 17. J Nucl Med. 2007. PMID: 17942807 Free article.

10

Positron emission tomography response criteria in solid tumours criteria for quantitative analysis of [18F]-fluorodeoxyglucose positron emission tomography with integrated computed tomography for treatment response assessment in metastasised solid tumours: All that glitters is not gold.

Willemsen AECAB, Vlenterie M, van Herpen CML, van Erp NP, van der Graaf WTA, de Geus-Oei LF, Oyen WJG. Willemsen AECAB, et al. Eur J Cancer. 2016 Mar;56:54-58. doi: 10.1016/j.ejca.2015.12.017. Epub 2016 Jan 22. Eur J Cancer. 2016. PMID: 26808297

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

69 results

Results by year